Disease · EFO_0009523

fecal incontinence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fecal incontinence. Diseases, record EFO_0009523. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009523

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fecal incontinence; Open Targets
Open Targets ID: EFO_0009523; Open Targets
Other names: Anal incontinence, Bowel incontinence, Loss of bowel control, faecal incontinence; Open Targets
MeSH: D005242; MeSH
NCI Thesaurus: C78498; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 24 drugs, from TTD; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PHENYLEPHRINE	CHEMBL1215	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LOPERAMIDE	CHEMBL841	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
CLONIDINE	CHEMBL134	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ILTAMIOCEL	CHEMBL4650237	Cell	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LACTULOSE	CHEMBL296306	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
COLESEVELAM HYDROCHLORIDE	CHEMBL1201473		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PHENYLEPHRINE HYDROCHLORIDE	CHEMBL1200339	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets31

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA2A	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
OPRM1	Mu-type opioid receptor	2	Mu opioid receptor agonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha agonist	Unknown	https://conductscience.org/library/genes/2099	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets

1 to 10 of 31

See all 31 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02008565	Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)	Phase 3	300	2018-11-20	Fecal Incontinence	LOPERAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02628626	A Study of Colesevelam in Fecal Incontinence	Phase 3	88	2023-06-22	Fecal Incontinence, Bile Acid Malabsorption	CLONIDINE, COLESEVELAM HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00727649	Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence	Phase 2/3	80	2015-04-01	Fecal Incontinence	LOPERAMIDE, PLANTAGO SEED	Its record names the disease	ClinicalTrials.gov
NCT01600755	Autologous Cell Therapy for Treatment of Fecal Incontinence	Phase 1/2	53	2024-02-16	Fecal Incontinence	ILTAMIOCEL	Its record names the disease	ClinicalTrials.gov
NCT00884832	A Placebo-Controlled Study of Clonidine for Fecal Incontinence.	Phase 2	44	2014-03-06	Fecal Incontinence	CLONIDINE	Its record names the disease	ClinicalTrials.gov
NCT01656720	A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period	Phase 2	417		Faecal Incontinence	METHOXAMINE	Its record names the disease	ClinicalTrials.gov
NCT05776277	Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury	Phase 3	200		Fecal Incontinence	ILTAMIOCEL	Its record names the disease	ClinicalTrials.gov
NCT07175805	Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy		200		Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist	SEMAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT06082622	Evaluation of the Triple Management Program in the Management of Functional Chronic Constipation in Children	Not applicable	180		Constipation Chronic Idiopathic	LACTULOSE, SODIUM PICOSULFATE	Its record names the disease	ClinicalTrials.gov
NCT06166615	The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence	Phase 2/3	147		Fecal Incontinence	PLANTAGO SEED, RAMOSETRON	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Colesevelam and Clonidine vs Placebo: deaths from any cause	0 of 24	0 of 32	56	NCT02628626	Trial comparisons
Colesevelam and Clonidine vs Placebo: serious adverse events	0 of 24	0 of 32	56	NCT02628626	Trial comparisons
Colesevelam and Clonidine vs Placebo: Number of Participants to Report a 50% or Greater Reduction in Weekly Fecal Incontinence (FI) Episodes	13 of 22	17 of 30	52	NCT02628626	Trial comparisons
Oral Clonidine vs Oral Placebo: serious adverse events	0 of 22	0 of 22	44	NCT00884832	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37144409	RESULT	1	PubMed
42975544	DERIVED	1	PubMed
41250992	DERIVED	1	PubMed
31320277	DERIVED	1	PubMed
26888731	DERIVED	1	PubMed
24943105	DERIVED	1	PubMed
23891925	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009523

GET https://conductscience.org/api/diseases/v1/EFO_0009523/drugs?page=2

API reference For AI assistants